TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04855656: Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

Sponsor: Debiopharm International SA · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 464 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$8,733,648

Rescue Site Savings

+$5,749,128

Unlock Full NCT04855656 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04855656 Rescue Dossier →